Citadel Advisors’s Third Harmonic Bio THRD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-27,800
Closed -$151K 14108
2025
Q2
$151K Sell
27,800
-28,500
-51% -$142K ﹤0.01% 10955
2025
Q1
$195K Buy
56,300
+56,200
+56,200% +$272K ﹤0.01% 10489
2024
Q4
$1.03K Sell
100
-7,000
-99% -$87.2K ﹤0.01% 14234
2024
Q3
$96.2K Sell
7,100
-2,000
-22% -$24.8K ﹤0.01% 11162
2024
Q2
$118K Buy
+9,100
New +$113K ﹤0.01% 10673

Other funds holding THRD

Citadel Advisors's THRD Position: Q3 2025 in Review

Citadel Advisors sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 120,870 shares — an estimated $656K sold.

Citadel Advisors first reported a position in THRD in Q3 2022 and held it in 8 quarters. The position peaked at $8.85M in Q2 2024. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • Citadel Advisors reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • Citadel Advisors sold 120,870 Third Harmonic Bio shares in Q3 2025, an estimated $656K.
  • Citadel Advisors first reported a position in Third Harmonic Bio in Q3 2022 and held it in 8 quarters.
  • Citadel Advisors's Third Harmonic Bio position peaked at $8.85M in Q2 2024.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.